Abstract Long‐term follow‐up of multiple myeloma (MM) clinical trials are needed to assess long‐term outcomes. We aimed to investigate the length of follow‐up of all phase III MM clinical trials. Median follow‐up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractory MM clinical trials (42.7 vs. 20.5 months, respectively). The follow‐up duration of phase III clinical trials in MM is relatively short when compared to the improved outcomes in the current era. Efforts should be made to facilitate long‐term clinical trials follow‐up and/or publication of results of updated results.
